ArticleCureus2026
Diagnostic Performance of AFP, PIVKA-II, and the ASAP Score for Distinguishing Hepatocellular Carcinoma With and Without Portal Vein Tumor Thrombus: A Retrospective Single-Center Study From Pakistan.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPortal vein tumor thrombus (PVTT) is an important manifestation of advanced hepatocellular carcinoma (HCC). Serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are established biomarkers associated with tumor burden, vascular invasion, and disease progression in HCC. However, their utility in distinguishing HCC patients with PVTT from those without PVTT remains poorly characterized in the Pakistani population.
methodsThis retrospective single-center study included 100 consecutive, newly diagnosed HCC patients: 46 with PVTT and 54 without PVTT. A separate group of 55 cancer-free controls was included solely for a secondary exploratory HCC-versus-control analysis. Diagnostic performance of AFP, PIVKA-II, and the Age-Sex-AFP-PIVKA-II (ASAP) score was evaluated using two-sided Mann-Whitney U tests, receiver operating characteristic (ROC) curve analysis, Youden index cutoffs, Spearman correlation, and multivariable logistic regression. ASAP values were calculated consistently from the raw variables before analysis.
resultsAFP and PIVKA-II were significantly higher in patients with PVTT than those without PVTT (AFP: p<0.001; PIVKA-II: p=0.030). AFP demonstrated the highest overall discriminatory performance for identifying PVTT, with an area under the ROC curve (AUROC) of 0.740 (95% confidence interval (CI): 0.642-0.837), achieving 78.3% sensitivity and 64.8% specificity at a cutoff value of 39.7 ng/mL. PIVKA-II yielded an AUROC of 0.627 (95% CI: 0.517-0.736), demonstrating high sensitivity (95.7%) but limited specificity (33.3%). The ASAP score achieved an AUROC of 0.688 (95% CI: 0.584-0.791) and did not outperform AFP. In multivariable logistic regression, natural logarithm-transformed (ln-transformed) AFP remained independently associated with PVTT (odds ratio: 1.249; 95% CI: 1.080-1.445; p=0.003), whereas ln-transformed PIVKA-II did not.
conclusionAmong patients with established HCC, AFP demonstrated better overall discriminatory performance than PIVKA-II for identifying PVTT, whereas PIVKA-II provided high sensitivity but limited specificity. The ASAP score did not improve diagnostic performance beyond AFP alone. These biomarkers may complement, but should not replace, contrast-enhanced imaging for the assessment of PVTT. Larger prospective multicenter studies are required to validate these findings before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.